U.S. respiratory virus levels continue their decline but shift seen in JN.1 mutations--CDC
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Respiratory virus activity from flu, COVID-19, and respiratory syncytial virus (RSV) continues to decline across most of the country, with only two jurisdictions—North Dakota and Wyoming—reporting high activity, the Centers for Disease Control and Prevention (CDC) said in updates today. ...
Hospitalizations continue to decline, but overall deaths were up slightly.
Submitted by mike kraft on
Amidst the anticipated increase in vaccine-preventable diseases as the global population ages, a first-of-its-kind study has underscored the dual benefits of adult immunization programs.
Submitted by mike kraft on
Activity from the three main respiratory viruses continues to decline in the United States, with one of the main flu markers—outpatient visits for flulike illness—now below the national baseline for the first time since October, the Centers for Disease Control and Prevention (CDC) said today in its latest updates for flu, COVID, and respiratory syncytial virus (RSV).
Submitted by mike kraft on
A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.
...
Submitted by mike kraft on
Submitted by mike kraft on
...
Submitted by mike kraft on
...
Submitted by mike kraft on
Submitted by mike kraft on